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santi.daniele@gmail.comAbstractIntroduction: The aim of this study is to comprehensively evaluate whether FSH
administration to the male partner of infertile couples improves pregnancy rate,
spontaneously and/or after assisted reproductive techniques (ART).
Methods: Meta-analysis of controlled clinical trials in which FSH was administered for male
idiopathic infertility, compared with placebo or no treatment. Randomization was not
considered as an inclusion criterion.
Results: We found 15 controlled clinical studies (614 men treated with FSH and 661 treated
with placebo or untreated). Concerning the type of FSH, eight studies used recombinant FSH,
whereas seven studies used purified FSH. Nine studies evaluated spontaneous pregnancy
rate, resulting in an overall odds ratio (OR) of about 4.5 (CI: 2.17–9.33). Eight studies
evaluated pregnancy rate after ART, showing a significant OR of 1.60 (CI: 1.08–2.37).
Sub-dividing studies according to the FSH preparations (purified/recombinant),
pregnancy rate improvement remained significant for each preparation. Eleven studies
considered sperm quality after FSH treatment, finding a significant improvement of
sperm concentration (2.66!106/ml, CI: 0.47–4.84), but not of concentration of sperm
with progressive motility (1.22!106/ml, CI: K0.07 to 2.52). Three trials evaluated
testicular volume, showing a non-significant increase in men treated (1.35 ml, CI: K0.44
to 3.14).
Conclusion: The results of controlled clinical trials available in the literature indicate an
improvement of pregnancy rate after FSH administration to the male partner of infertile
couples, both spontaneously and after ART. However, the heterogeneity of studies, the high
risk of bias and the lack of precise criteria to guide FSH administration limit the strength of
these results. Future studies should be designed to identify the markers of FSH response
which are helpful in the decision-making process. Meanwhile, the use of FSH in the
treatment of male infertility should be cautious.Key Words
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2–13 4 :R47IntroductionRationale
Infertility is conventionally defined as a clinical condition
affecting a couple failing to conceive after a period of
12 months of regular intercourse without contraception (1).
Male infertility plays a significant role inw50% of couples
experiencing a delay in conceiving (2). A careful and
complete diagnostic workup allows for recognition of the
most important male infertility causes (3). However, the
underlying pathophysiological mechanism remains idio-
pathic in about 30% of cases, which fall in the category of
’male idiopathic infertility’(2). The medical treatment of
infertility may be specific or non-specific. Specific treat-
ments are used for certain etiologies, such as hypogonado-
tropic hypogonadism, male accessory gland infection,
retrograde ejaculation, and positive antisperm antibody
(4). Non-specific treatments are hormonal and non-
hormonal therapies, proposed for the treatment of
idiopathic infertile men (5, 6).
Assisted reproductive techniques (ART) based on IVF
were introduced to clinical practice in 1978 (7), and
progressively extended its indication from female, tubal
infertility to unexplained couple infertility. Currently,
intracytoplasmatic-sperm injection (ICSI) is the most
frequently used ART (8). The outcome of ICSI seems to
be influenced by sperm structure and quality (9). Thus, it
seems reasonable that an improvement in sperm quality
could effect ICSI outcomes.
The empirical administration of follicle stimulating
hormone (FSH) to infertile men has been reported in the
literature since 1991 to variably improve fertilization and
pregnancy rate (10, 11). This therapy is popular in some
countries, although doubts remain on its efficacy in the
treatment of infertile men, particularly in the ART setting.
A significant increase in pregnancy rate after IVF and male
treatment with FSH was shown in some studies (12, 13),
while other trials did not find the same improvement (14).
Recently, the Cochrane Collaboration estimated the
overall effect of FSH treatment of the man in couples
attending ART enrolled in randomised, controlled, clinical
trials (15). This meta-analysis demonstrates that FSH
treatment significantly improves spontaneous pregnancy
rate, whereas no improvement of pregnancy rate is
observed after ART, probably because only one random-
ized clinical trial (RCT) was included (15). These results
were obtained by evaluating only randomized, controlled,
clinical trials, using fixed and strict inclusion criteria (15).
The authors excluded quasi-RCTs, cross-over trials (if datahttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0050
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Published by Bioscientifica Ltdbefore the cross-over was not available), and excluded all
trials in which randomization was not carried out (15).
Therefore, only six RCTs, the most recent thereof
published in 2006 (16), were included in the meta-
analysis. The absence of further RCTs in this field of
medicine in the last decade reflects the difficulty of
conducting a randomized approach in infertile couples,
in which the woman is nearing the end of her reproductive
age, as a swift successful pregnancy is required. Finally,
Attia et al. (15) evaluated pregnancy rate as an outcome of
FSH treatment without assessing separately purified and
recombinant FSH formulations.Objectives
The aim of this study was to comprehensively evaluate
whether FSH administration to the male partner of
infertile couples improves pregnancy rate, spontaneously
and/or after ART, by performing a meta-analysis of all
controlled clinical trials.Materials and methods
We performed a meta-analysis according to the Cochrane
Collaboration and PRISMA statement (17, 18).Data sources and searches
We conducted a comprehensive literature search for
English-language articles inMEDLINE (PubMed), EMBASE,
the Cochrane Library, SCOPUS and UpToDate. Search
key words were: FSH, FSH treatment, FSH therapy, follicle-
stimulating hormone, gonadotropin, infertility, male
infertility, IVF, intracytoplasmatic sperm injection, IVF,
ICSI and the Boolean functions AND and OR.Study selection and inclusion criteria
Types of studies " Controlled clinical trials in which
FSH was administered for male idiopathic infertility,
compared with placebo or no treatment. Randomization
was not considered as inclusion criterion, thus both
randomized and non-RCTs were reviewed.
Type of participants " Men with idiopathic infertility
or subfertility. All semen abnormalities (from mild
oligozoospermia to severe oligo-astheno-teratospermia)This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
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3–13 4 :R48were considered eligible, independently of the changes
over time of the normality ranges for semen analysis by
theWorld Health Organization (WHO). Azoospermic men
were not considered eligible. Controls were not treated or
placebo-treated idiopathic infertile or sub-fertile men.
No inclusion criteria were applied for the female partner
of the infertile couple.
Type of interventions " Chronic treatment with any
type of FSH, compared with placebo or no treatment.Data collection process and quality
One author (D S) extracted the abstracts from all studies
found through the literature search. All abstracts were
evaluated for inclusion criteria and data were extracted
from each study considered eligible, with regard to study
design, year of publication, number of included/excluded
subjects, number of dropped-out patients and the use of
intention to treat/per protocol analysis. Furthermore, D S
extracted study subjects’ demographics and underlying
diseases, with particular attention to the time elapsed from
the first attempt to conceive.
All controlled study designs were considered eligible.
We included studies assessing efficacy of FSH adminis-
tration to the male partner of infertile couples in order to
improve fertilization. The quality of trials was assessed
using the parameters proposed by Jadad et al. (19) and
Table 1 summarizes the features of the selected studies.
Studies considered in the meta-analysis used different
endpoints. Some studies evaluated spontaneous pregnancy
rate, occurring after unprotected intercourse, whereas
other studies evaluated fertilization and pregnancy rate
occurring after ART. We performed an overall meta-
analysis which considered all studies that evaluated
pregnancy rate. Subsequently, we separately evaluated
pregnancy rate, either spontaneously or after ART.
Semen analysis, a surrogate fertility marker, was
routinely performed using light microscopy. In all studies,
semen samples were collected by masturbation, generally
after 3–4 days of sexual abstinence, and liquefied at 37 8C.
The other investigators (M S, A R G) performed quality
control checks on the extracted data (Fig. 1). The
investigators, using the Cochrane risk-of-bias algorithm,
independently assessed the risk of bias for all trials (20).
The following quality criteria and methodological details
were evaluated for each trial included in themeta-analysis:
i) method of randomization, even if the randomization
was not an inclusion criterion, ii) concealment of
allocation, iii) presence or absence of blinding tohttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0050
 2015 Society for Endocrinology
Published by Bioscientifica Ltdtreatment allocation, iv) duration and type of treatment
and follow-up phases, v) number of participants recruited,
analyzed or lost to follow-up, vi) timing of trial, vii) whether
an intention to treat analysis was done, viii) whether a
power calculation was done, ix) source of funding, and
x) criteria for includingparticipants andassessingoutcomes.Summary measures
The primary outcome was pregnancy rate, evaluated as an
odds ratio (OR) between treated and control men.
Secondary outcomes were semen analysis parameters.
Sperm quality (i.e. sperm concentration and progressive
motility) and testicular volume were considered as mean
differences. Sperm motility was assessed as the number of
progressive motile sperm, calculated considering only the
percentage of sperm with progressive motility out of the
total sperm number.
Data synthesis and analysis
The meta-analysis was conducted using the Review
Manager (RevMan) 5.3 Software (Version 5.3.1 Copen-
hagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014). Data were combined using the
fixed effect model for the primary endpoint, considering
the reliability in the evaluation of pregnancy. However,
the random effect model was used for secondary end-
points, providing a more conservative estimate of the
overall effect, considering the intrinsic inaccuracy of
parameters such as sperm quality. Weighted mean
differences and 95%CIs were estimated for each endpoint.
Heterogeneity among the results of different studies was
examined by inspecting both the scatter in the data points
and the overlap in their CIs, and by performing c2 tests
and I2 statistics. The I2 statistics answer the question:
what proportion of the observed variance reflects real
differences in effect size? It is a measure of inconsistency
across the findings of the studies, not a measure of the real
variation across the underlying true effects. Values of
P!0.05 were considered statistically significant.Risk of bias across studies
The authors (D S, A R G, M S) independently evaluated risk
of bias. Publication bias is a bias towards reporting
significant results, despite the fact that studies with
significant results do not appear to be superior to studies
with a null result with respect to result quality (21, 22).
A simple analysis of funnel plots provides a useful test forThis work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
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Table 1 Characteristics of studies included in the meta-analysis.
References
Number of
treated
patients
Number of
control
patients
Mean age
(years)
Baseline
sperm
concentration
of treated
patients
(million/ml)
Baseline
sperm
morphology
of treated
patients (%)
Baseline
FSH of
treated
patient
(IU/l)
Baseline
Sperm
concentration
of controls
(million/ml)
Baseline
sperm
morphology
of controls
(%)
Baseline
FSH of
controls
(IU/l) Drugs
Cumulative
FSH dose
(IU)
Duration
(weeks)
Parameters
evaluated
(12) 39 39 – – – – – – – Purified FSH
(Metrodin)
6300 12 PR
(14) 24 20 – 8.81 – – 12.42 – – Purified FSH
(Fertinorm)
12 600 12 PR, FR, semen
analysis
(35) 31 101 31.5 – – – – – – Purified FSH
(Metrodin)
2100 4 PR, semen
analysis
(36) 20 20 31.7 – – 6.4G2.4 – – 6.4G2.6 Purified FSH
(Metrodin)
– 2 IVF cycles PR, FR
(37) 23 10 35.3 1.3G2.2 23.9G8.2 9.7G6.05 2.5G2.2 30.0G12.9 10.5G6.8 Recombinant
FSH (Gonal F)
5400 12 PR, FR, TV,
semen
analysis
(38) 65 63 32.6 7.8G2.7 20.6G5.0 5.9G1.3 8.1G2.2 21.8G4.7 6.1G1.6 Recombinant
FSH (Gonal F)
6750 12 Semen
analysis,
sDF
(41)a 77 20 32 4.7G5.1 – 9.0G8.9 61.2G38.8 – 2.6G1.6 Purified FSH
(Metrodin)
3375 12 Semen
analysis
(40)a 30 55 32.6 4.8G2.6 – 4.1G2.2 63.2G39.2 2.8G1.5 Recombinant
FSH (Gonal F)
2250 12 Semen
analysis
(39) 65 90 34.2 6.4G3.5 25.3G6.2 4.6G1.2 6.8G3.2 26.2G6.8 4.8G1.4 Recombinant
FSH (Gonal F)
4500 12 PR, semen
analysis
(42) 57 62 34.2 1.8G0.7 20.7G8.4 15.1G5.8 1.7G0.9 18.1G9.9 14.7G6.6 Recombinant
FSH (Gonal F)
6750 12 PR, semen
analysis
(13) 34 33 32.8 8.7G1.5 33.4G3.0 5.0G0.4 8.7G1.6 29.6G3.0 5.6G0.6 Recombinant
FSH (Gonal F)
12 600 12 PR, semen
analysis, TV
(43) 19 20 – – – – – – – hMG – 13 PR
(44)a 58 78 – 69.5G40.7 27.5G11.8 – 72.3G43.2 30.3G12.3 – Purified FSH
(Fertinorm)
– unclear PR, semen
analysis
(16) 15 15 – 7.6G3.6 9.4G6.1 4.1G1.6 7.4G4.1 8.7G5.5 4.3G1.8 Recombinant
FSH (Gonal F)
18 000 16 PR, semen
analysis
(45) 70 35 – 4.0G4.2 20.8G15.4 5.0G1.8 3.8G4.0 20.1G16.3 4.9G2.0 Recombinant
FSH (Gonal F)
5400 12 PR, semen
analysis, TV
hMG, human menopausal gonadotropin, FR, fertilization rate, FSH, follicle-stimulating hormone, PR, pregnancy rate, sDF, sperm-DNA fragmentation, TV, testicular volume.
aStudies in which untreated normozoospermic infertile men of infertile couples were enrolled in the control group.
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Records indentified through
database searching
(n=3699)
Records after first screening
(n=568)
Records screened
(n=568)
Records excluded
(n=537)
Full text articles
assessed for eligibility
(n=30)
Studies included in
qualitative and
quantitative analysis
(n=15)
Full text articles
excluded, with reasons
(n=15)
Figure 1
Study flow chart showing the search results for the studies included in the
meta-analysis.
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5–13 4 :R50the likely presence of bias in meta-analyses, but as the
capacity to detect bias will be limited when meta-analyses
are based on a limited number of small trials, the results
from such analyses should be treated with considerable
caution (22). Funnel and Egger’s plots were performed
using RevMan Software.Additional analysis
Comparison between variables was performed with the
Mann–Whitney U test. Meta-regression analysis was
conducted by comparing sperm parameters to pregnancy
rate. Number needed to treat (NNT) was calculated as the
statistical inverse ratio of the absolute OR reduction. All
additional analyses were performed using ‘Statistical
Package for the Social Sciences’ Software for Macintosh
(version 20.0; SPSS, Inc.).Results
Study selection
Figure 1 shows the literature searching process, conducted
from September 2014 to January 2015. From 568 studieshttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0050
 2015 Society for Endocrinology
Published by Bioscientifica Ltdinitially found according to the research strategy, we
identified 30 potentially relevant studies, based on the
information given in the abstract. All trials were
thoroughly appraised for eligibility in the meta-analysis
and methodological quality. Fifteen studies were excluded
from the final analysis since they did not fulfill the
inclusion criteria (9, 10, 11, 23, 24, 25, 26, 27, 28, 29, 30,
31, 32, 33, 34). Four studies were excluded because they
were neither controlled nor cross-over studies (10, 11, 33, 34).
Three studies were excluded because, although they aimed
at evaluating the effect of gonadotropins in infertile
couples, the study design did not provide the enrollment
and the treatment criteria for themale partner (23, 25, 27).
Four studies were excluded because they evaluated
pregnancy rate in hypogonadotropic hypogonadic men
(24, 30, 31, 32). Another trial was excluded because it
evaluated the effect on sperm retrieval after testicular
sperm extraction in azoospermic men after treatment with
clomiphene citrate (26). Furthermore, another work was
excluded because it was only a letter and not an original
article (28). Finally, two studies were excluded because
they were not clinical trials but reviews of sperm
characteristics related to fertility (9, 29). Fifteen studies
met the inclusion criteria (12, 13, 14, 16, 35, 36, 37, 38, 39,
40, 41, 42, 43, 44, 45) (Figure 1).Study characteristics
All trials included were controlled against placebo or no
treatment and enrolled the male partners of infertile
couples attending ART Centers. By definition, the term
‘infertility’ was used after at least 1 year of unsuccessful
intercourse (1). However, the duration of infertility
considered in each study was different. Some trials
considered infertile couples failing to conceive after
1 year, others after 2 years of unprotected intercourse.
Furthermore, the definition of infertility in each trial was
different. Some studies enrolled men with severe oligo-
asthenoteratozoospermia, whereas others enrolled men
with mild to moderate semen abnormalities, i.e. astheno-
zoospermia or teratozoospermia. The definition of these
semen abnormalities was different, reflecting the WHO
criteria, which changed during the time frame of the
studies included.
Concerning the type of FSH, eight studies included in
the meta-analysis used recombinant FSH (13, 16, 37, 38,
39, 40, 42, 45), whereas seven studies used purified FSH
(12, 14, 36, 41, 43, 44). Since the efficacy of recombinant
and purified FSH was demonstrated to be similar (46)
the type of FSH was not considered a source of bias.This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
AUTHOR COPY ONLY
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6–13 4 :R51Pregnancy rate, when evaluated, was considered spon-
taneous or after ART.
The different inclusion and exclusion criteria used in
the studies included represent the most important source
of heterogeneity in the estimation of the overall effect.
This is a typical selection bias in studies involving infertile
patients, considering several factors could influence
couple fertility, from either the male or from the female
side. The selected trials gave details about 1275 infertile
men, 614 treated with FSH and 661 untreated (545) or
placebo-treated (116).Risk of bias in included studies
Figure 2 summarizes the risk of bias.
Allocation (selection bias) " Nine studies were RCTs
and precisely specified themethodology of randomization
(12, 13, 14, 38, 39, 40, 42, 43, 45). The other six studies
included were non-randomized, controlled, clinical trials,
with potential selection bias due to the lack of
randomization.
Blinding (performance bias and detection
bias) " The nine RCTs were double-blinded (12, 13, 14,
38, 39, 40, 42, 43, 45).
Incomplete outcome data (attrition bias) " The
drop-out rate of patients enrolled in the trials included
was similar. Only five trials correctly reported the drop-out
rate, and the evaluation of data after drop-out (13, 38, 39,
42, 44). The remaining studies included in the meta-
analysis neither reported the drop-out rate nor gave
information about the evaluation of patient drop-out.
Selective reporting (reporting bias) " The primary
endpoints described in the aims were reported in theRandom sequence generation (selection bia
Allocation concealment (selection bia
Blinding of participants and personnel (performance bia
Blinding of outcome assessment (detection bia
Incomplete outcome data (attrition bia
Selective reporting (reporting bia
Low risk of bias Unclea
Figure 2
Risk of bias graph: the authors’ judgement about each risk of bias item is prese
http://www.endocrineconnections.org
DOI: 10.1530/EC-15-0050
 2015 Society for Endocrinology
Published by Bioscientifica Ltdresults section of each study. Several studies included
secondary endpoints, which, however, were not always
completely reported in the results and discussion sections.
Other potential sources of bias " None of the trials
reported a calculation of the sample size in the study
design.
Synthesis of results
Considering the lack of a unique, validated pharmaco-
dynamics marker of FSH administration inmen, the major
endpoint of FSH treatment efficacy in male infertility is
pregnancy rate. Among the 15 studies included, 12 trials
considered pregnancy rate after FSH administration to the
male partner, for a total of 482 infertile men treated,
compared to 393 control men (12, 13, 14, 16, 35, 36, 37,
39, 42, 43, 44, 45) (Fig. 3A). First of all, baseline FSH levels
were generally within or slightly above the normal range.
There were no significant differences in basal FSH serum
levels between treated and not-treated men (6.89C3.48 vs
6.27C3.69 mIU/ml, PZ0.052). On the contrary, sperm
concentration at baseline was significantly higher in the
group of men not treated with FSH, compared to those
treated (22.56C27.91 vs 11.40C19.44!106/ml,
P!0.001), confirming a lack of randomization.
A significant improvement in pregnancy rate was
found in treated men. The overall OR was 2.09 with CI
1.46–3.01 (P!0.001) (Fig. 3A). c2 was 10.09 and
I2 statistics 0% (Fig. 3A). The I2 statistics showed a low
degree of inconsistency of this result. Significant improve-
ment in pregnancy rate remained dividing the analysis in
randomized (OR 1.55, CI 1.0–2.4, PZ0.05), and not-RCTs
(OR 3.96, CI 1.87–8.37, P!0.001).
Assessing pregnancy rate, we further performed two
subgroup meta-analyses, keeping spontaneous and ART
pregnancies seperate. The first subgroup analysis includeds)
s)
s)
s)
s)
s)
r risk of bias High risk of bias
0% 25% 50% 75% 100%
nted as percentages across all included studies.
This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
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7–13 4 :R52nine studies in which spontaneous pregnancy rate was
reported or evaluated as the main outcome (12, 13, 16, 37,
39, 42, 43, 44, 45). A total of 384 men were treated,
compared to 308 controls during the study protocol. The
pregnancy rate improved significantly after FSH treat-
ment, with an OR of about 4.5, with a CI 2.17–9.33
(P!0.001) (Fig. 3B). c2 was 2.29 and I2 statistics 0%
(Fig. 3B). This increased pregnancy rate was confirmed
both in five RCTs (OR 5.15, CI 2.01–13.15, P!0.001), and
in four not-RCTs (OR 3.70, CI 1.17–11.73, PZ0.003),
suggesting that the lack of randomization did not impair
the result. The second subgroup meta-analysis considered
eight studies evaluating pregnancy rate after ART, inde-
pendently of the ART methods applied (12, 13, 14, 36, 37,
39, 42, 44). A total of 322 men were treated, compared to
275 controls. Pregnancy rate significantly improved after
FSH treatment, with an OR of about 1.60 and CI 1.08–2.37
(PZ0.002) (Fig. 3C). c2 was 12.22 and I2 statistics 43%
(Fig. 3C). Pregnancy rate improved in not-RCTs (OR 1.57,
CI 1.04–2.37, PZ0.03), whereas it did not change in RCTs.
This lack of a significant increase in randomized trials is
probably due to the very low number (only one) of
RCTs included.
NNT calculation indicated that ten men should be
treated to achieve one spontaneous pregnancy and
18 men to achieve pregnancy after ART.
Considering FSH dosages, regimens and formulations,
the studies included in the meta-analytic process were
heterogeneous. Table 1 shows the FSH formulation used in
each study and the cumulative FSH dose. The mean
duration of FSH administration was 11.77G2.59 weeks
and the mean cumulative FSH dose used was 7168.75G
4815.47 IU. No linear correlation between mean duration
of FSH administration and pregnancy rate was found
(PZ0.581). Similarly, cumulative FSH dose did not
significantly correlate with pregnancy rate (PZ0.076).
We subdivided the analysis into two sub-analyses,
considering studies using recombinant (Fig. 3D) and
purified FSH (Fig. 3E), respectively. The significant
increase of pregnancy rate was confirmed, independently
of the FSH preparation chosen (PZ0.007, OR 3.49 and
PZ0.002, OR 7.11 for recombinant and purified FSH,
respectively).
Another meta-analysis was performed in order to
assess the overall effect of FSH administration on semen
parameters, evaluated by light microscopy. We considered
11 studies reporting sperm concentration after FSH
treatment (13, 14, 16, 37, 38, 39, 40, 41, 42, 44, 45).
A total of 520menwere treated, compared to 427 controls.
The meta-analysis showed a significant improvement ofhttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0050
 2015 Society for Endocrinology
Published by Bioscientifica Ltdsperm concentration after FSH administration, with a
mean improvement of 2.66!106/ml (CI 0.47–4.84)
(PZ0.02) (Fig. 4A). c2 was 206.08 and I2 statistics 95%
(Fig. 4A). Furthermore, we analyzed six studies which
considered progressive sperm motility (13, 37, 38, 41, 44,
45). A total of 332 men were treated, compared to 297
controls. The meta-analysis showed a non-significant
improvement of progressive sperm motility after FSH
and the mean improvement was 1.22!106/ml (CI K0.07
to 2.52) (PZ0.06) (Fig. 4B). c2 was 1851.9 and I2 statistics
100% (Fig. 4B).
Three trials reported testicular volume (13, 37, 45).
A total of 127 FSH-treated men and 76 controls were
compared. The results showed an increase of testicular
volume in FSH-treated men, but this increase was not
statistically significant (PZ0.14). The mean increase was
1.35 ml, with CIK0.44 to 3.14. c2 was 2.68 and I2 statistics
25%. Considering the two studies in which testicular
volume was evaluated by ultrasonography, this parameter
did not change after FSH treatment (PZ0.44) (13, 45).
In particular, Selice et al. (45) gave neither any
information about the mathematical formula used for
testicular volume calculation by ultrasonography, nor
found any significant variation in this parameter after
treatment. In contrast, Kamischke et al. (13) reported the
method applied for testicular volume calculation and
found a significant increase after FSH treatment. These
discrepancies do not demonstrate a clear FSH effect on
testicular size.Additional analysis
Meta-regression analysis showed no significant correlation
between pregnancy rate and sperm concentration,
progressive motility and testicular volume (PZ0.502,
PZ0.175 and PZ0.854, respectively). Sperm concen-
tration correlations were not found with progressive
motility, nor with testicular volume (PZ0.925 and
PZ0.203, respectively).
The visual evaluation of funnel plots did not reveal
publication bias in the studies considered.Discussion
Here we confirm the beneficial effect of FSH adminis-
tration to the male partner of couples with idiopathic
infertility in terms of pregnancy rate improvement, either
spontaneously or after ART. This finding extends that
recently obtained by the Cochrane Collaboration which
was limited to spontaneous pregnancy (15). Some featuresThis work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
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9–13 4 :R54of our meta-analysis are, however, different. In particular,
we used broader inclusion criteria, due to the difficulty in
performing RCTs in the field of infertility, demonstrated
by the lack of randomized studies on FSH for male
infertility published in the last decade. Furthermore, we
analysed the treatment effect on pregnancy rate while
distinguishing between the FSH formulations used.
Finally, we estimated the overall effect of FSH treatment
on other outcomes, i.e sperm concentration, progressive
sperm motility and testicular volume.
Considering pregnancy rate, this meta-analysis
confirms the beneficial effect of FSH administration to
the male partner of infertile couples, demonstrating an
improvement in spontaneous pregnancies (15). Further-
more, we demonstrate, for the first time, that FSH
administration to the male partner is able to increase
pregnancy rate after ART, independent of the ART
methodology. This improvement in pregnancy rate
remains even when recombinant or purified FSH are
considered separately, suggesting that the two FSH
preparations have a similar efficacy (Fig. 3D and E).
Similarly, an improved pregnancy rate was confirmed
when randomized and not-RCTs were considered separ-
ately, suggesting that lack of randomization does not
impair the quality of the results. However, these results
should be viewed in light of the broad inclusion criteria
and high risk of bias. With this in mind, pregnancy rate
increases in men treated with FSH, even if the OR is low,
and additional analysis suggests that 10–18 men should be
treated to achieve one additional pregnancy. This might
sound marginal, but considering the costs of ART and the
woman’s burden for the treatment of male infertility
versus the cost of FSH treatment (irrespective of recombi-
nant or extractive), this option should be given a trial.
The best tool for the evaluation of male fertility in
clinical practice remains semen analysis. However, its
interpretation is difficult, because of the inherent varia-
bility of the parameters and lack of clear-cut threshold
values (47, 48). Several studies demonstrated a beneficial
effect of FSH on the quality of spermatozoa (9, 14, 49), and
an algorithm was proposed to improve the interpretation
of semen analysis (49). Our results demonstrate an
improvement of sperm concentration after treatmentFigure 3
Pregnancy rate. (A) Forest plot of 15 studies evaluating pregnancy rate
after FSH administration. (B) Forest plot of nine studies evaluating
spontaneous pregnancy rate after FSH administration. (C) Forest plot
of eight studies evaluating pregnancy rate during ART, after FSH
http://www.endocrineconnections.org
DOI: 10.1530/EC-15-0050
 2015 Society for Endocrinology
Published by Bioscientifica Ltdwith FSH (Fig. 4A and B). However, a high degree of
heterogeneity was evident (I2 of 95%) and progressive
sperm motility did not significantly improve after treat-
ment. We interpret this difference as a sign of methodo-
logical inconsistency in semen analysis itself (48), as well
as a heterogeneity of the inclusion criteria of the patients.
Even if conventional semen analysis does not provide
accurate information about the spermatozoa’s ability to
fertilize the egg, this meta-analysis demonstrates that FSH
administration to infertile men improves sperm concen-
tration and increases pregnancy rate. However, no
correlation between sperm parameters and pregnancy
rate was found. Evaluating the baseline characteristics of
patients enrolled, we found that basal FSH serum levels
were not different between study and control groups. Men
not treated with FSH have higher baseline sperm concen-
tration compared to treated men, reflecting the fact that
some of the included studies were not randomized.
Considering these limits, FSH administration increases
sperm concentration irrespective of the basal FSH serum
levels and absolute sperm number. This result suggests
that basal FSH serum levels and sperm concentration do
not represent a useful marker in the decision making
process of whether to treat or not. Sperm morphology is a
weak parameter, considering the spontaneous variability
over the years, as evident from the different thresholds
proposed by the various editions of the WHO manual to
define normal morphology. Considering that studies
included in the meta-analysis were conducted using
different WHO manuals, it is not possible to compare
this parameter with a statistical approach. Finally, other
parameters, such as sperm DNA fragmentation, could be
useful in the future to direct the decision-making process
of whether or not to treat infertile men (38).
In animal models, FSH administration stimulates
spermatogenesis and increases Sertoli cell secretions (50).
In monkeys, the proliferation of spermatogenetic cells,
together with Sertoli cells secretions, results in a testicular
volume increase after 6 weeks of FSH administration (50).
Some studies in men reported a testicular enlargement
caused by a FSH-secreting pituitary adenoma (51) followed
by a significant volume reduction after normalization of
FSH levels (51). Since Sertoli cell number is constant afteradministration. The results are divided according to the use of recombinant
(D) or purified (E) FSH. The diamond indicates the overall summary estimate
for the analysis (width of the diamond represents the 95% CI); boxes
indicate the weight of individual studies in the pooled analysis.
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10–13 4 :R55puberty, any increase in testicular volume should be
primarily due to increased spermatogenesis (13). There-
fore, FSH treatment of male infertility could increase
testicular volume. This hypothesis was suggested by some
clinical trials (13, 32, 37). However, our meta-analysis did
not find any significant improvement after FSH treatment.
This result is limited by the high heterogeneity of the
studies included in this subgroup of the meta-analysis
(I2Z93%), possibly related to the inconsistency of
methods used for testicular volume measurement (52).
Testicular volume calculation by ultrasonography is more
accurate and precise than comparative evaluation per-
formed by orchidometry (53). However, several math-
ematical formula for testicular volume are proposed in the
literature, but only one study included in our meta-
analysis specified the methodology used (13). In our meta-
analysis the lack of testicular volume increase after FSH
treatment remains when considering the two studies in
which ultrasonography was performed. Thus, the FSH-
induced improvement of sperm concentration without a
significant increase in testicular size remains intriguing.http://www.endocrineconnections.org
DOI: 10.1530/EC-15-0050
 2015 Society for Endocrinology
Published by Bioscientifica LtdIn conclusion, FSH administration to infertile men
improves pregnancy rate, even if the OR is low and 10–18
men need to be treated to achieve one additional
pregnancy. However, treated men were very hetero-
geneous and the usefulness of FSH treatment probably
depends on the precise definition of the baseline
condition and selection criteria of the infertile man. The
studies included in the meta-analysis are limited by:
i) empirical unstandardized FSH treatment use;
ii) heterogeneity of the infertile men enrolled;
iii) heterogeneity of the studies included, possibly related
to an unknown female factor, as suggested by the relative
high risk of bias (Fig. 2); iv) different lengths of treatment
and follow-up phases used. Our results show the impossi-
bility of defining a basal FSH serum level or basal sperm
concentration which could distinguish responders
from non-responders. Other predictors of response to
FSH treatment should be identified, considering the
relevance in clinical practice of distinguishing those men
who will respond to FSH treatment from those who will
not. A pharmacogenetic approach was suggested (54) andThis work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
AUTHOR COPY ONLY
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11–13 4 :R56could help the decision-making process while new
fertility-related markers need to be identified to quantify
the efficacy of FSH treatment. New markers, such as sperm
DNA fragmentation (38), could help clinicians in the
decision-making process, both as a prediction marker and
pharmacodynamics parameter of FSH treatment.
However, this parameter requires further evaluation.Conclusions
FSH administration to the male is sometimes used for the
empirical treatment of infertile couples. However, its
efficacy remains unclear. The results of the clinical trials
available in the literature, considered together in this
meta-analysis, indicate an improvement of pregnancy rate
after FSH administration to the male partner of infertile
couples, both spontaneously or after ART. Furthermore,
this meta-analysis suggests an improvement of sperm
concentration after FSH administration, without a testi-
cular size increase. However, a standardized FSH treatment
protocol of male idiopathic infertility does not exist. Since
a specific predictor of response to FSH administration is not
available, the use of FSH in men with infertility should be
judicious. Future clinical trials should bedesigned todefine
who will and who will not respond to FSH treatment.Declaration of interest
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